Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25125
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBeauchamp, Leah C-
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorFinkelstein, David I-
dc.contributor.authorDoré, Vincent-
dc.contributor.authorBush, Ashley I-
dc.contributor.authorBarnham, Kevin J-
dc.contributor.authorRowe, Christopher C-
dc.date2020-10-23-
dc.date.accessioned2020-10-27T03:57:12Z-
dc.date.available2020-10-27T03:57:12Z-
dc.date.issued2020-10-23-
dc.identifier.citationScientific Reports 2020; 10(1): 17631en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/25125-
dc.description.abstractMotor deficits in parkinsonism are caused by degeneration of dopaminergic nigral neurons. The success of disease-modifying therapies relies on early detection of the underlying pathological process, leading to early interventions in the disease phenotype. Healthy (n = 16), REM sleep behavior disorder (RBD) (n = 14), dementia with Lewy bodies (n = 10), and Parkinson's disease (PD) (n = 20) participants underwent 18F-AV133 vesicular monoamine transporter type-2 (VMAT2) PET to determine the integrity of the nigrostriatal pathway. Clinical, neurophysiological and neuropsychological testing was conducted to assess parkinsonian symptoms. There was reduced VMAT2 levels in RBD participants in the caudate and putamen, indicating nigrostriatal degeneration. RBD patients also presented with hyposmia and anxiety, non-motor symptoms associated with parkinsonism. 18F-AV133 VMAT2 PET allows identification of underlying nigrostriatal degeneration in RBD patients. These findings align with observations of concurrent non-motor symptoms in PD and RBD participants of the Parkinson's Progression Markers Initiative. Together, these findings suggest that RBD subjects have prodromal parkinsonism supporting the concept of conducting neuroprotective therapeutic trials in RBD-enriched cohorts. Ongoing longitudinal follow-up of these subjects will allow us to determine the time-window of clinical progression.en
dc.language.isoeng-
dc.titleReduced striatal vesicular monoamine transporter 2 in REM sleep behavior disorder: imaging prodromal parkinsonism.en
dc.typeJournal Articleen
dc.identifier.journaltitleScientific Reportsen
dc.identifier.affiliationThe Australian E-Health Research Centre, CSIRO Health and Biosecurity, Melbourne, Australiaen
dc.identifier.affiliationMolecular Imaging and Therapyen
dc.identifier.affiliationDepartment of Medicine, The University of Melbourne, Melbourne, Australiaen
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Australiaen
dc.identifier.affiliationThe Department of Pharmacology and Therapeutics, The University of Melbourne, Melbourne, Australiaen
dc.identifier.affiliationMelbourne Dementia Research Centre, The University of Melbourne, Parkville, Australiaen
dc.identifier.doi10.1038/s41598-020-74495-xen
dc.type.contentTexten
dc.identifier.pubmedid33097764-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

46
checked on Jul 2, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.